Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(2002): Baselga J+, J Clin Oncol 20(21), 4292
(2002): Herbst RS+, J Clin Oncol 20(18), 3815 (46%) (follicular)
(2002): Van Doorn R+, Br J Dermatol 147(3), 598
(1995): Salomon DS+, Crit Rev Oncol Hematol 19(3), 183
Acute generalized exanthematous pustulosis (AGEP)
(2006): Shih HC+, Br J Dermatol 155(5), 1101 (2 cases)
Adverse effects (sic)
(2004): Perras C, Issues Emerg Health Technol 150(55), 1
(2004): Ranson M+, J Clin Pharm Ther 29(2), 95
(2004): Rich JN+, J Clin Oncol 22(1), 133
Desquamation (39%)
(2006): Graves JE+, JAmAcad55(2), 349
(2004): Lee MW+, Acta Derm Venereol 84(1), 23 (39%)
Exanthems
(2005): Kurokawa I+, Int J Dermatol 44(2), 167
(2004): Schlessinger J, Omaha, NE (from Internet) (observation)
Exfoliative dermatitis
(2006): Cersosimo RJ, Expert Opin Drug Saf 5(3), 469
Folliculitis
(2006): Kirby AM+, Br J Cancer 94(5), 631
(2006): Matheis P+, JAmAcadDermatol55(4), 710
(2005): Treudler R+, Dermatology 211(4), 375
(2002): Van Doorn R+, Br J Dermatol 147(3), 598
Glucagonoma syndrome
(2003): Trojan A+, Swiss Med Wkly 133(1), 22
Hand–foot syndrome
(2006): Razis E+, Cancer Invest 24(5), 514 (recall) (3 cases)
Pigmentation
(2004): Chang GC+, J Clin Oncol 22(22), 4646
Pruritus (52%)
(2004): Cappuzzo F+, Br J Cancer 90(1), 82 (52.6%)
(2004): Forsythe B+, Drug Saf 27(14), 1081
Pyoderma gangrenosum
(2006): Sagara R+, Int J Dermatol 45(8), 1002
Rash (sic) (52%)
(2007): Fury MG+, Cancer Chemother Pharmacol 59(4), 467
(2007): Gadgeel SM+, J Thorac Oncol 2(4), 299
(2006): Chang A+, J Thorac Oncol 1(8), 847
(2006): Chou LS+, Clin Lung Cancer 8 Suppl 1, S15
(2006): Dudek AZ+, Lung Cancer 51(1), 89
(2006): Jubelirer SJ+, WVMedJ102(6), 14
(2006): Maurel J+, Int J Radiat Oncol Biol Phys 66(5), 1391 (with
gemcitabine)
(2006): Perez-Soler R, Clin Lung Cancer 8 Suppl 1, S7
(2006): Seiverling EV+, J Drugs Dermatol 5(4), 368
(2005): Canil CM+, J Clin Oncol 23(3), 455
(2005): Mohamed MK+, Ann Oncol 16(5), 780
(2005): Pascual JC+, Br J Dermatol 153(6), 1222
(2005): Perez-Soler R+, J Clin Oncol 23(22), 5235
(2005): Razis E+, Anticancer Drugs 16(2), 191
(2004): Argiris A+, Lung Cancer 43(3), 317
(2004): Cappuzzo F+, Br J Cancer 90(1), 82 (52.6%)
(2004): Cersosimo RJ, Am J Health Syst Pharm 61(9), 889
(2004): Forsythe B+, Drug Saf 27(14), 1081
(2004): Janne PA+, Lung Cancer 44(2), 221
(2004): Mu XL+, BMC Cancer 4, 51
(2003): Perez-Soler R, Oncology (Huntingt) 17(11 Suppl 12), 23
(2002): Culy CR+, Drugs 62(15), 2237
(2000): Meric JB+, Bull Cancer 87(12), 873
Rosacea
(2004): Aylesworth R, Rhinelander, WI (from Internet)
(observation)
Scaling
(2002): Van Doorn R+, Br J Dermatol 147(3), 598
Seborrhea
(2006): Cersosimo RJ, Expert Opin Drug Saf 5(3), 469
(2006): Graves JE+, JAmAcad55(2), 349
Toxicity (sic)
(2007): Yoshida K+, J Thorac Oncol 2(1), 22
(2006): Cusatis G+, J Natl Cancer Inst 98(23), 1739
(2006): Lin WC+, Lung Cancer 54(2), 193
(2004): Herbst RS+, J Clin Oncol 22(5), 785
Ulcerations
(2004): Lee MW+, Acta Derm Venereol 84(1), 23 (nasal)
Urticaria
(2004): Lee MW+, Acta Derm Venereol 84(1), 23
Xerosis (39–52%)
(2006): Cersosimo RJ, Expert Opin Drug Saf 5(3), 469
(2006): Graves JE+, JAmAcadDermatol55(2), 349
(2004): Cappuzzo F+, Br J Cancer 90(1), 82 (52.6%)
(2004): Forsythe B+, Drug Saf 27(14), 1081
(2004): Lee MW+, Acta Derm Venereol 84(1), 23 (39%)
Mucosal
Oral ulceration
(2004): Lee MW+, Acta Derm Venereol 84(1), 23
Stomatitis
(2006): Cersosimo RJ, Expert Opin Drug Saf 5(3), 469
Hair
Hair – abnormal texture
(2006): Graves JE+, JAmAcadDermatol55(2), 349
Hair – alopecia
(2006): Graves JE+, JAmAcadDermatol55(2), 349
Hair – hypertrichosis
(2002): Van Doorn R+, Br J Dermatol 147(3), 598
GEFITINIB 247
Nails
Nails – changes (sic) (17%)
(2006): Lin WC+, Lung Cancer 54(2), 193
Nails – paronychia (6%)
(2007): Tjin-A-Ton ML+, Ned Tijdschr Geneeskd 151(17), 945 (2
cases)
(2006): Graves JE+, JAmAcadDermatol55(2), 349
(2004): Chang GC+, J Clin Oncol 22(22), 4646
(2004): Davidson D, Groton, CT (all fingers) (from Internet)
(observation)
(2004): Lee MW+, Acta Derm Venereol 84(1), 23 (6%)
(2004): Thaler D, Monona, WI (from Internet) (observation)
(2003): Dainichi T+, Dermatology 207(3), 324
(2003): Nakano J+, JDermatol30(3), 261
(2002): Di Lernia V Reggio Emilia, Italy (from Internet)
(observation)
Nails – pyogenic granulomas
(2006): High WA, Arch Dermatol 142(7), 939
Eyes
Blepharitis
(2006): Cersosimo RJ, Expert Opin Drug Saf 5(3), 469
Conjunctivitis
(2006): Cersosimo RJ, Expert Opin Drug Saf 5(3), 469
Eyelashes – hypertrichosis
(2004): Pascual JC+, Br J Dermatol 151(5), 1111
Other
Abdominal pain
(2006): Cersosimo RJ, Expert Opin Drug Saf 5(3), 469
Anaphylactoid reactions/Anaphylaxis
(2004): Perras C, Issues Emerg Health Technol 55, 1
Anorexia
(2006): Jubelirer SJ+, WVMedJ102(6), 14
Death
(2005): Aoe K+, Anticancer Res 25(1B), 415
(2003): Rabinowits G+, Anticancer Drugs 14(8), 665
Epistaxis
(2006): Cersosimo RJ, Expert Opin Drug Saf 5(3), 469
Hepatotoxicity
(2006): Carlini P+, J Clin Oncol 24(35), e60
(2005): Ho C+, J Clin Oncol 23(33), 8531